advertisement
Ahmed F 36
Showing records 1 to 25 | Display all abstracts from Ahmed F118227 Cyclodiode vs micropulse transscleral laser treatment
Kelada M
Eye 2024; 38: 1477-1484
117728 Artificial intelligence in glaucoma: opportunities, challenges, and future directions
Huang X
Biomedical engineering online 2023; 22: 126
118704 NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs
Galli C
Journal of Ocular Pharmacology and Therapeutics 2024; 40: 389-396
117135 ANGPTL7 and Its Role in IOP and Glaucoma
Brown SF
Investigative Ophthalmology and Visual Science 2024; 65: 22
117728 Artificial intelligence in glaucoma: opportunities, challenges, and future directions
Islam MR; Islam MR
Biomedical engineering online 2023; 22: 126
117135 ANGPTL7 and Its Role in IOP and Glaucoma
Nguyen H
Investigative Ophthalmology and Visual Science 2024; 65: 22
118227 Cyclodiode vs micropulse transscleral laser treatment
Normando EM
Eye 2024; 38: 1477-1484
117728 Artificial intelligence in glaucoma: opportunities, challenges, and future directions
Islam MR
Biomedical engineering online 2023; 22: 126
118704 NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs
Bastia E
Journal of Ocular Pharmacology and Therapeutics 2024; 40: 389-396
117135 ANGPTL7 and Its Role in IOP and Glaucoma
Mzyk P
Investigative Ophthalmology and Visual Science 2024; 65: 22
117728 Artificial intelligence in glaucoma: opportunities, challenges, and future directions
Akter S
Biomedical engineering online 2023; 22: 126
118227 Cyclodiode vs micropulse transscleral laser treatment
Cordeiro FM
Eye 2024; 38: 1477-1484
118704 NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs
Hubatsch DA
Journal of Ocular Pharmacology and Therapeutics 2024; 40: 389-396
117135 ANGPTL7 and Its Role in IOP and Glaucoma
Mzyk P; De Ieso ML
Investigative Ophthalmology and Visual Science 2024; 65: 22
118704 NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs
Toris C
Journal of Ocular Pharmacology and Therapeutics 2024; 40: 389-396
118227 Cyclodiode vs micropulse transscleral laser treatment
Crawley L
Eye 2024; 38: 1477-1484
117728 Artificial intelligence in glaucoma: opportunities, challenges, and future directions
Ahmed F
Biomedical engineering online 2023; 22: 126
118227 Cyclodiode vs micropulse transscleral laser treatment
Ahmed F
Eye 2024; 38: 1477-1484
117135 ANGPTL7 and Its Role in IOP and Glaucoma
Unser AM
Investigative Ophthalmology and Visual Science 2024; 65: 22
118704 NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs
Fan S
Journal of Ocular Pharmacology and Therapeutics 2024; 40: 389-396
117728 Artificial intelligence in glaucoma: opportunities, challenges, and future directions
Kazami E
Biomedical engineering online 2023; 22: 126
117135 ANGPTL7 and Its Role in IOP and Glaucoma
Brown I
Investigative Ophthalmology and Visual Science 2024; 65: 22
118227 Cyclodiode vs micropulse transscleral laser treatment
Ameen S
Eye 2024; 38: 1477-1484
117728 Artificial intelligence in glaucoma: opportunities, challenges, and future directions
Serhan HA
Biomedical engineering online 2023; 22: 126
118704 NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs
Unser A
Journal of Ocular Pharmacology and Therapeutics 2024; 40: 389-396
